GlassScriptPhysician profile
Lora Hargett
NPI 1497348155
$12,821.00
in general payments reported to CMS, 2019-2025
40 companies · $3,302 in 2025
The $3,302 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,447 · 2022: $1,874 · 2023: $2,728 · 2024: $3,471 · 2025: $3,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,367 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,366.78 |
| Education | $133.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,569.90 | 2022-2025 | Spravato, Invega Sustenna |
| Novo Nordisk INC | $1,467.62 | 2021-2025 | Wegovy |
| Abbvie INC. | $1,173.66 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,036.87 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $991.11 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $888.30 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $873.57 | 2022-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $722.63 | 2022-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $431.75 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $395.67 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $362.31 | 2022-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $352.43 | 2022-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $315.04 | 2023-2025 | Quviviq, Quviviq |
| Novartis Pharmaceuticals Corporation | $253.12 | 2021-2022 | |
| Insulet Corporation | $229.34 | 2021-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $214.87 | 2024-2025 | Cobenfy |
| Astrazeneca Pharmaceuticals LP | $181.04 | 2021 | |
| Tris Pharma INC | $142.06 | 2022-2024 | Dyanavel Xr |
| Bausch Health US, LLC | $138.92 | 2022-2025 | Wellbutrin, Aplenzin |
| Corium, LLC | $131.03 | 2022-2025 | Azstarys |
| Noven Therapeutics, LLC | $117.08 | 2023-2025 | Xelstrym, Secuado |
| Neos Therapeutics, LP | $114.31 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.40 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $77.38 | 2022-2024 | Jornay Pm |
| Indivior INC. | $77.33 | 2022-2025 | Sublocade |
| Almatica Pharma LLC | $66.87 | 2025 | Loreev Xr |
| Amarin Pharma, INC. | $58.57 | 2021 | |
| Merck Sharp & Dohme LLC | $46.33 | 2022-2023 | Belsomra |
| Xeris Pharmaceuticals, INC. | $40.01 | 2021 | |
| Collegium Pharmaceutical, INC. | $39.25 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $36.82 | 2023-2024 | Subvenite, Lamotrigine |
| Lundbeck LLC | $33.98 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $27.55 | 2021-2022 | |
| Amgen INC. | $26.78 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $20.45 | 2021 | |
| Currax Pharmaceuticals LLC | $17.97 | 2025 | Contrave |
| Brainsway USA INC | $16.96 | 2022 | |
| Biogen, INC. | $16.06 | 2024 | |
| Angiodynamics, INC. | $14.49 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.17 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Hargett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.